Report ID : 10352360 |
Published Date : 21 Mar 2025 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Asia Pacific Cancer Screening Market Highlights Over 2020 - 2030
The Asia Pacific cancer screening market is estimated to garner a revenue of USD 142542.43 Million by the end of 2030, by growing at a CAGR of 13.37% over the forecast period, i.e., 2021 – 2030. Moreover, in the year 2020, the market in the region generated a revenue of USD 40982.90 Million. The growth of the market can majorly be attributed to the rising incidences of cancer in the region, which according to the statistics by the World Health Organization (WHO) is anticipated to grow from 9.50 Million in the year 2020 to 15.1 Million in the year 2040. Cancer is one of the leading causes of death, and has taken the lives of 5.81 Million people in the year 2020, according to the WHO. The surge in cancer cases in the region along with the growing concern for the rising number of deaths caused due to the disease, is driving the need for early diagnosis and treatment of the disease, which is anticipated to contribute to the growth of the market in the coming years.
CLICK TO DOWNLOAD SAMPLE REPORT
In addition to this, the growing medical industry in the Asia Pacific, along with the increasing health expenditure in the region is also anticipated to drive the growth of the market in the coming years. According to the statistics by the World Bank, the current health expenditure per capita in the East Asia & Pacific increased from USD 478.291 (in current US$) in the year 2010 to USD 720.909 in the year 2018. Further, the increasing advancements in screening technology, including screening devices and reagents used for testing of the disease, is also projected to create numerous opportunities for the market growth in the coming years.
Asia Pacific Cancer Screening Market Regional Synopsis
By country, the Asia Pacific cancer screening market is segmented into Australia, Japan, Singapore, South Korea, India, China, Taiwan, Vietnam, Thailand, Philippines, and the Rest of Asia Pacific. The market in China is anticipated to garner the largest revenue of USD 62861.21 Million by the end of 2030, up from a revenue of USD 17376.75 Million in the year 2020. The growth of the market in the country can primarily be attributed to the presence of large number of cancer patients, followed by the presence of numerous research organizations who are working tirelessly to develop advanced screening devices for the early diagnosis of the disease. In the other statistics by the WHO, the incidences of cancer in China registered 4.57 Million in the year 2020, and is further projected to reach 6.85 Million by the end of 2040. On the other hand, the market in Japan is projected to generate the second-largest revenue of USD 24374.76 Million by the end of 2030, up from a revenue of USD 6926.11 Million in the year 2020.
Growth Drivers and Challenges Impacting the Growth of the Asia Pacific Cancer Screening Market
Growth Drivers
-
Increasing Incidences of Cancer
-
Developing Medical Sector in Asia Pacific
Challenges
-
High Costs Associated with Cancer Disease Imaging Systems
-
Lack of Skilled Technicians for Performing Screening of the Disease
Asia Pacific Cancer Screening Market Segmentation Synopsis
The Asia Pacific cancer screening market is segmented by screening type into laboratory tests, genetic tests, imaging, biopsy, endoscopy, and others. Out of these, the imaging segment is projected to garner the largest revenue of USD 52365.97 Million by the end of 2030, up from a revenue of USD 15039.41 Million in the year 2020. By product, the market is segmented into consumables, and instruments. Out of these, the consumables segment is projected to garner the largest revenue by the end of 2030 and also grow with the highest CAGR of 13.73% during the forecast period. By application, the market is segmented into lung cancer, breast cancer, melanoma, kidney cancer, colorectal cancer, and others. Out of these, the lung cancer segment is anticipated to generate the second-largest revenue of USD 31055.18 Million by the end of 2030, up from a revenue of USD 8603.68 Million in the year 2020. By end-user, the market is segmented into hospitals & clinics, laboratories, and others. Out of these, the hospitals & clinics segment is anticipated to garner the largest revenue of USD 101732.53 Million by the end of 2030, up from a revenue of USD 28786.12 Million by the end of 2020.
Key Companies Dominating the Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the Asia Pacific cancer screening market that are included in our report are Abbott, General Electric, Hologic, Inc., Siemens Healthcare Private Limited, QIAGEN, F. Hoffmann-La Roche Ltd., Illumina, Inc., Novacyt Group, Koninklijke Philips N.V., MiRXES Pte Ltd., and others.
Latest Developments in the Asia Pacific Cancer Screening Market:
-
May 27th, 2019: Siemens Healthcare Private Limited announced that Apollo Hospital, Chennai (India), has deployed the first digital PET/CT – Biograph Vision device of Siemens. The device, which is first of its kind, would help in delivering the right treatment to the right cancer patient at the right time, and would address cancer progression.
-
July 1st, 2021: QIAGEN announced that it has partnered with Sysmex Corporation of Japan for the commercialization and development of cancer companion diagnostics. The strategic alliance between the two companies will help leverage both the companies for next generation sequencing (NGS) and for the development of drug treatments for cancer.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
1. Market Definition
1.1. Definition
1.2.Market Segmentation
2. Assumptions and Acronyms
3. Research Methodology
3.1.Research Process
3.2. Primary Research
3.3. Secondary Research
4. Executive Summary – Asia Pacific Cancer Screening Market
5. Analysis of Market Dynamics
5.1. Market Drivers
5.2. Market Restraints
6. Key Market Opportunities
7. Major Roadblocks for the Market Growth
8. Regulatory Landscape
9. Industry Risk Analysis
10. Pricing Analysis of Cancer Screening Market
11. Value Chain Analysis
12.Analysis on the Major Cancer Screening Tools
13.Industry Growth Outlook
14.Impact of COVID-19 on the Asia Pacific Cancer Screening Market
15. Asia Pacific Cancer Screening Market 2020-2030
15.1. Market Overview
15.2. By Value (USD Million)
15.3. Market Segmentation
15.3.1. By Screening Type
15.3.1.1. Laboratory Tests, 2020-2030F (USD Million)
15.3.1.2. Genetic Tests, 2020-2030F (USD Million)
15.3.1.3. Imaging, 2020-2030F (USD Million)
15.3.1.4. Biopsy, 2020-2030F (USD Million)
15.3.1.5. Endoscopy, 2020-2030F (USD Million)
15.3.1.6. Others, 2020-2030F (USD Million)
15.3.2. By Product
15.3.2.1. Consumables, 2020-2030F (USD Million)
15.3.2.2. Instruments, 2020-2030F (USD Million)
15.3.3. By Application
15.3.3.1. Lung Cancer, 2020-2030F (USD Million)
15.3.3.2. Breast Cancer, 2020-2030F (USD Million)
15.3.3.3. Melanoma, 2020-2030F (USD Million)
15.3.3.4. Kidney Cancer, 2020-2030F (USD Million)
15.3.3.5. Colorectal Cancer, 2020-2030F (USD Million)
15.3.3.6. Gastric Cancer, 2020-2030F (USD Million)
15.3.3.7. Others, 2020-2030F (USD Million)
15.3.4. By End-User
15.3.4.1. Hospitals & Clinics, 2020-2030F (USD Million)
15.3.4.2. Laboratories, 2020-2030F (USD Million)
15.3.4.3. Others, 2020-2030F (USD Million)
15.3.5. By Country
15.3.5.1. Australia, 2020-2030F (USD Million)
15.3.5.2. Japan, 2020-2030F (USD Million)
15.3.5.3. Singapore, 2020-2030F (USD Million)
15.3.5.4. South Korea, 2020-2030F (USD Million)
15.3.5.5. India, 2020-2030F (USD Million)
15.3.5.6. China, 2020-2030F (USD Million)
15.3.5.7. Taiwan, 2020-2030F (USD Million)
15.3.5.8. Vietnam, 2020-2030F (USD Million)
15.3.5.9. Thailand, 2020-2030F (USD Million)
15.3.5.10. Philippines, 2020-2030F (USD Million)
15.3.5.11. Rest of Asia Pacific, 2020-2030F (USD Million)
16.Australia Cancer Screening Market 2020-2030
16.1. Market Overview
16.2. By Value (USD Million)
16.3. Market Segmentation
16.3.1. By Screening Type
16.3.1.1. Laboratory Tests, 2020-2030F (USD Million)
16.3.1.2. Genetic Tests, 2020-2030F (USD Million)
16.3.1.3. Imaging, 2020-2030F (USD Million)
16.3.1.4. Biopsy, 2020-2030F (USD Million)
16.3.1.5. Endoscopy, 2020-2030F (USD Million)
16.3.1.6. Others, 2020-2030F (USD Million)
16.3.2. By Product
16.3.2.1. Consumables, 2020-2030F (USD Million)
16.3.2.2. Instruments, 2020-2030F (USD Million)
16.3.3. By Application
16.3.3.1. Lung Cancer, 2020-2030F (USD Million)
16.3.3.2. Breast Cancer, 2020-2030F (USD Million)
16.3.3.3. Melanoma, 2020-2030F (USD Million)
16.3.3.4. Kidney Cancer, 2020-2030F (USD Million)
16.3.3.5. Colorectal Cancer, 2020-2030F (USD Million)
16.3.3.6. Gastric Cancer, 2020-2030F (USD Million)
16.3.3.7. Others, 2020-2030F (USD Million)
16.3.4. By End-User
16.3.4.1. Hospitals & Clinics, 2020-2030F (USD Million)
16.3.4.2. Laboratories, 2020-2030F (USD Million)
16.3.4.3. Others, 2020-2030F (USD Million)
17. Japan Cancer Screening Market 2020-2030
17.1. Market Overview
17.2. By Value (USD Million)
17.3. Market Segmentation
17.3.1. By Screening Type
17.3.2. By Product
17.3.3. By Application
17.3.4. By End-User
18.Singapore Cancer Screening Market 2020-2030
18.1. Market Overview
18.2. By Value (USD Million)
18.3. Market Segmentation
18.3.1. By Screening Type
18.3.2. By Product
18.3.3. By Application
18.3.4. By End-User
19.South Korea Cancer Screening Market 2020-2030
19.1. Market Overview
19.2. By Value (USD Million)
19.3. Market Segmentation
19.3.1. By Screening Type
19.3.2. By Product
19.3.3. By Application
19.3.4. By End-User
20. India Cancer Screening Market 2020-2030
20.1. Market Overview
20.2. By Value (USD Million)
20.3. Market Segmentation
20.3.1. By Screening Type
20.3.2. By Product
20.3.3. By Application
20.3.4. By End-User
21.China Cancer Screening Market 2020-2030
21.1. Market Overview
21.2. By Value (USD Million)
21.3. Market Segmentation
21.3.1. By Screening Type
21.3.2. By Product
21.3.3. By Application
21.3.4. By End-User
22. Taiwan Cancer Screening Market 2020-2030
22.1. Market Overview
22.2. By Value (USD Million)
22.3. Market Segmentation
22.3.1. By Screening Type
22.3.2. By Product
22.3.3. By Application
22.3.4. By End-User
23. Vietnam Cancer Screening Market 2020-2030
23.1. Market Overview
23.2. By Value (USD Million)
23.3. Market Segmentation
23.3.1. By Screening Type
23.3.2. By Product
23.3.3. By Application
23.3.4. By End-User
24. Thailand Cancer Screening Market 2020-2030
24.1. Market Overview
24.2. By Value (USD Million)
24.3. Market Segmentation
24.3.1. By Screening Type
24.3.2. By Product
24.3.3. By Application
24.3.4. By End-User
25. Philippines Cancer Screening Market 2020-2030
25.1. Market Overview
25.2. By Value (USD Million)
25.3. Market Segmentation
25.3.1. By Screening Type
25.3.2. By Product
25.3.3. By Application
25.3.4. By End-User
26. Rest of Asia Pacific Cancer Screening Market 2020-2030
26.1. Market Overview
26.2. By Value (USD Million)
26.3. Market Segmentation
26.3.1. By Screening Type
26.3.2. By Product
26.3.3. By Application
26.3.4. By End-User
27. Competitive Landscape
27.1. Company Market Share Analysis
27.2. Company Profiles
27.2.1. Abbott
27.2.2. General Electric
27.2.3. Hologic, Inc.
27.2.4. Siemens Healthcare Private Limited
27.2.5. QIAGEN
27.2.6. F. Hoffmann-La Roche Ltd.
27.2.7. Illumina, Inc.
27.2.8. Novacyt Group
27.2.9. Koninklijke Philips N.V.
27.2.10. MiRXES Pte Ltd.
